BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Aberrant oncogene and tumor suppressor expression drives cervical cancer (CC) pathogenesis.
• B-cell CLL/lymphoma 3 (BCL3) is a proto-oncogene implicated in cancers, potentially regulating signal transducer and activator of transcription 3 (STAT3) in CC.
• The role of BCL3 in CC remains largely undefined.

Purpose of the Study:

• To investigate the expression, clinical significance, and biological functions of BCL3 in cervical cancer.
• To elucidate the relationship between BCL3, STAT3, and cervical cancer progression.
• To determine if STAT3 mediates the oncogenic effects of BCL3 in CC.

Main Methods:

• Immunohistochemistry to assess BCL3 and STAT3 expression in CC tissues.
• In vitro assays (MTT, colony formation, flow cytometry) to evaluate proliferation and cell cycle.
• In vivo xenograft mouse models to assess tumor growth.
• Western blotting to confirm protein levels.

Main Results:

• BCL3 is overexpressed in CC tissues and cells, correlating with adverse prognosis and reduced survival.
• BCL3 overexpression enhances CC cell proliferation and cell cycle progression; BCL3 inhibition suppresses these effects.
• BCL3 positively regulates STAT3 expression, and STAT3 mediates BCL3's oncogenic functions in CC.
• Knockdown of BCL3 inhibits CC tumor growth in vivo.

Conclusions:

• BCL3 functions as an oncogene in cervical cancer by promoting proliferation and cell cycle progression.
• The oncogenic activity of BCL3 in CC is mediated through its downstream target, STAT3.
• BCL3 represents a potential therapeutic target for cervical cancer.